Ireland-based Jazz Pharmaceuticals will buy U.S.-based Celator Pharmaceuticals in a cash deal valued at about $1.5 billion, to gain access to an investigational product in development for treating acute myeloid leukemia.
Jazz Pharmaceuticals will pay $30.25 per share in cash for Celator, a 72.6% premium to Celator’s closing price on Friday.
Read Full Article »
